1990
A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients
Roberts R, Jurica K, Meyer W, Paxton H, Makuch R. A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients. The Journal Of Infectious Diseases 1990, 162: 638-642. PMID: 2117625, DOI: 10.1093/infdis/162.3.638.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase 1 studyDaily dosesAdverse reactionsTreatment groupsHuman immunodeficiency virus-infected patientsPatients' peripheral blood mononuclear cellsHIV surrogate markersT lymphocyte subsetsVirus-infected patientsClinical adverse reactionsAnti-HIV effectDemonstrable beneficial effectsHuman immunodeficiency virusBlood mononuclear cellsOral ribavirinP24 antigenemiaLymphocyte subsetsTotal lymphocytesSerum betaImmunodeficiency virusLymphocyte markersMononuclear cellsLymphocyte populationsSurrogate marker
1988
Statistical Methods for the Analysis of HIV-1 Core Polypeptide Antigen Data in Clinical Studies
Makuch R, Parks W. Statistical Methods for the Analysis of HIV-1 Core Polypeptide Antigen Data in Clinical Studies. AIDS Research And Human Retroviruses 1988, 4: 305-316. PMID: 3061416, DOI: 10.1089/aid.1988.4.305.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsInitiation of therapyPlacebo-controlled studyHIV-1 antigensDemonstrated clinical efficacyHIV-1 coreAntiretroviral effectClinical efficacyAIDS patientsAntiretroviral activityClinical studiesLymphocyte culturesVirus expressionSerum dataAntigen dataPatientsSurvival analysis methodsLaboratory dataAZTGroup differencesMost laboratory dataCulture dataStatistical methodsSignificant declineSerum
1985
Histologic assessment of lymph nodes in mycosis fungoides/sézary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system
Sausville E, Worsham G, Matthews M, Makuch R, Fischmann A, Schechter G, Gazdar A, Bunn P. Histologic assessment of lymph nodes in mycosis fungoides/sézary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system. Human Pathology 1985, 16: 1098-1109. PMID: 3876976, DOI: 10.1016/s0046-8177(85)80177-5.Peer-Reviewed Original ResearchMeSH KeywordsHumansLymph NodesLymphocytesLymphomaMycosis FungoidesPrognosisSezary SyndromeSkin NeoplasmsT-LymphocytesConceptsCutaneous T-cell lymphomaLymph node biopsy specimensFive-year survivalLymph node architectureLymph nodesAtypical cellsHistopathologic featuresBiopsy specimensMycosis fungoides/Sézary syndromeLymph node biopsyAtypical lymphoid cellsT-cell lymphomaExtent of skinT-cell regionsLN subgroupAtypical lymphocytesNode biopsySézary syndromeVisceral involvementMycosis fungoidesInitial diagnosisParacortical zonePrognostic valueLN classHistopathologic classification
1980
Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity
Baskies A, Chretien P, Weiss J, Makuch R, Beveridge R, Catalona W, Spiegel H. Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 1980, 45: 3050-3060. PMID: 7388749, DOI: 10.1002/1097-0142(19800615)45:12<3050::aid-cncr2820451229>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsDepressed cellular immunityLymphocyte reactivityCellular immunityCancer patientsAlpha 2 HS-glycoproteinAlbumin levelsTumor extentHS-glycoproteinVivo parametersLevels of haptoglobinLevels of APPSerum glycoprotein levelsSerum protein levelsSerum glycoproteinsOngoing trialsPreoperative patientsRegional tumorsSerum levelsImmune statusImmunologic functionSolid malignanciesNormal controlsPatientsGlycoprotein levelsPrimary site